medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2004, Number 2

<< Back

Rev Mex Patol Clin Med Lab 2004; 51 (2)

Behavior of the prostate specific antigen (PSA) value with two different immunoenzymatic methods

García FI, Pereda MCM, Hernández RO, García LM, Sinconegui GB, González HJ, Bouzó LA

Language: Spanish
References: 16
Page: 119-122
PDF size: 49.60 Kb.


ABSTRACT

Introduction: The prostate specific antigen (PSA) it’s one of the most important tumor antigen for the prostate cancer’s diagnosis an follow up. The normal prostate cells and prostate malignancies produced this antigen. It could be found in normal range in prostate tissue cells and its raising could be associated with an irregularity in the normal prostate process, because the prostatitis are associate with the raise in the PSA concentrations. Methods and materials: We measure the PSA concentrations through two different methods: A Radioimmunoassays double site called (IRMA) and immunoenzimatic assays called EIA. Results and discussion: We found no difference between the results measured by both methods p < 0.00001. The Pearson's correlation for the two methods was (0.99938; p < 0.000001. Conclusions: The PSA values for the two methods were similar and there is a good correlation between them.


REFERENCES

  1. Mazzucchelli R, Colanzi P, Pomante R, Muzzonigro G, Montironi R. Prostate tissue and serum markers. Adv Clin Path 2000; 4 (3): 111-120.

  2. Hoffman RM, Clanon DL, Chavez M, Pierce J. Using multiple for free-to-total prostate specific antigen ratio improves the accuracy of prostate cancer detection. Prostate 2002; 52 (2): 150-158.

  3. Fowler JE, Bigler SA, Miles D, Yalkut DA. Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer. J Urol 2000; 163 (3): 813-818.

  4. Sanderbrg AA. Chromosomal abnormalities and related events in prostatic cancer. Human Pathol 1992; 23: 368-380.

  5. Bostwick DG. Prostatic intraepithelial neoplasia. Urol 1989; 34 (suppl): 52-56.

  6. Sakr WA. High grade prostatic intraepithelial neoplasia (HGPIN) and adenocarcinoma between the ages of 28-69: an autopsy study of 249 cases. In Vivo 1994; 8: 439-441.

  7. Lalani-el-N, Laniado-ME, Abel-PD. Molecular and cellular biology of prostate cancer. Cancer Metastasis Rev 1997; 16 (1-2): 29-66.

  8. Thompson IM, Chodak GW. The natural history of adenocarcinoma of prostate. J Cell Biochem 1992; 16H: 20-23 (27).

  9. Berger AP, Spranger R, Kofler K, Steiner H, Bartsch G, Horniger W. Early detection of prostate cancer with low cut-off values leads to significant stage migration in radical prostatectomy specimens. Prostate 2003; 57 (2): 93-98.

  10. Lipski-BA, Garcia-RL, Brawer-MK. Prostatic intraepithelial neoplasia: Significance and management. Semin Urol Oncol 1996; 14 (3): 149-155.

  11. Myers RB, Grizzle WE. Biomarker expression in prostatic intraepithelial neoplasia. Eur Urol 1996; 30 (2): 153-166.

  12. Bostwick DG. Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Eur Urol 1996; 30 (2): 145-152.

  13. Oesterling J et al. Cancer of the genitourinary system. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principle and practices of oncology. 5th ed. Philadelphia. NY, 1997: 1322-1386.

  14. Zlotta AR, Schulman CC. Clinical evolution of prostatic intraepithelial neoplasia. Eur Urol 199; 35: 498-503.

  15. Mai KT, Isotalo PA, Green J, Perkins DG, Morash C, Collins JP. Incidental prostatic adenocarcinomas and putative premalignant lesions in TURP specimens collected before and after the introduction of prostate-specific antigen screening. Arch Pathol Lab Med 2000; 124 (10): 1454-1456.

  16. Morote J, Encabo G, Lopez M, de Torres IM. Influence of high-grade prostatic intra-epithelial neoplasia on total and percentage free serum prostatic specific antigen. BJU Int 1999; 84 (6): 657-660.




2020     |     www.medigraphic.com